Skip to main content
NCBI home page
Infection and Immunity logoLink to Infection and Immunity
. 1993 Mar;61(3):975–980. doi: 10.1128/iai.61.3.975-980.1993

Estimation of protective levels of anti-O-specific lipopolysaccharide immunoglobulin G antibody against experimental Escherichia coli infection.

D E Schiff 1, C A Wass 1, S J Cryz Jr 1, A S Cross 1, K S Kim 1
PMCID: PMC302828  PMID: 7679376

Abstract

Serum obtained after immunization with an O18 polysaccharide-toxin A conjugate vaccine was evaluated for the estimation of protective levels of anti-O-specific lipopolysaccharide (LPS) immunoglobulin G (IgG) antibody against bacteremia and death caused by a homologous serotype of Escherichia coli K1 strains. Passive transfer of rabbit serum conferred significant protection from a lethal E. coli infection in a neonatal rat model. The overall incidence of bacteremia and mortality was 4% in rat pups receiving undiluted postvaccination serum, while that in control animals was 100% (P < 0.001). The overall incidences of bacteremia were 5 and 72% for animals with serum anti-O18 LPS IgG concentrations of > 1.0 and < 1.0 microgram/ml, respectively, while the overall incidences of mortality for animals with serum anti-O18 LPS IgG levels of > 1.0 and < 1.0 microgram/ml were 0 and 72%, respectively (P < 0.001). Protection against E. coli infection was also demonstrated with human anti-O18 polysaccharide IgG. None of the animals with human anti-O18 LPS IgG levels of > 1 microgram/ml had bacteremia after bacterial challenge, whereas all animals with bacteremia at 18 h had levels of < 1 microgram/ml. These findings suggest that serum anti-O18 LPS IgG concentrations of > 1.0 microgram/ml may provide protection against bacteremia and death caused by a homologous E. coli K1 infection.

Full text

PDF
975

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bryan C. S., Reynolds K. L., Brenner E. R. Analysis of 1,186 episodes of gram-negative bacteremia in non-university hospitals: the effects of antimicrobial therapy. Rev Infect Dis. 1983 Jul-Aug;5(4):629–638. doi: 10.1093/clinids/5.4.629. [DOI] [PubMed] [Google Scholar]
  2. Cross A. S., Gemski P., Sadoff J. C., Orskov F., Orskov I. The importance of the K1 capsule in invasive infections caused by Escherichia coli. J Infect Dis. 1984 Feb;149(2):184–193. doi: 10.1093/infdis/149.2.184. [DOI] [PubMed] [Google Scholar]
  3. Cross A. S., Zollinger W., Mandrell R., Gemski P., Sadoff J. Evaluation of immunotherapeutic approaches for the potential treatment of infections caused by K1-positive Escherichia coli. J Infect Dis. 1983 Jan;147(1):68–76. doi: 10.1093/infdis/147.1.68. [DOI] [PubMed] [Google Scholar]
  4. Cryz S. J., Jr, Cross A. S., Sadoff J. C., Fürer E. Synthesis and characterization of Escherichia coli O18 O-polysaccharide conjugate vaccines. Infect Immun. 1990 Feb;58(2):373–377. doi: 10.1128/iai.58.2.373-377.1990. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Cryz S. J., Jr, Cross A. S., Sadoff J. C., Wegmann A., Que J. U., Fürer E. Safety and immunogenicity of Escherichia coli O18 O-specific polysaccharide (O-PS)-toxin A and O-PS-cholera toxin conjugate vaccines in humans. J Infect Dis. 1991 May;163(5):1040–1045. doi: 10.1093/infdis/163.5.1040. [DOI] [PubMed] [Google Scholar]
  6. Cryz S. J., Jr, Fürer E., Cross A. S., Wegmann A., Germanier R., Sadoff J. C. Safety and immunogenicity of a Pseudomonas aeruginosa O-polysaccharide toxin A conjugate vaccine in humans. J Clin Invest. 1987 Jul;80(1):51–56. doi: 10.1172/JCI113062. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Cryz S. J., Jr, Fürer E., Sadoff J. C., Fredeking T., Que J. U., Cross A. S. Production and characterization of a human hyperimmune intravenous immunoglobulin against Pseudomonas aeruginosa and Klebsiella species. J Infect Dis. 1991 May;163(5):1055–1061. doi: 10.1093/infdis/163.5.1055. [DOI] [PubMed] [Google Scholar]
  8. Haemophilus influenzae type b: disease and immunity in humans. Ann Intern Med. 1973 Feb;78(2):259–269. doi: 10.7326/0003-4819-78-2-259. [DOI] [PubMed] [Google Scholar]
  9. Kaijser B., Ahlstedt S. Protective capacity of antibodies against Escherichia coli and K antigens. Infect Immun. 1977 Aug;17(2):286–289. doi: 10.1128/iai.17.2.286-289.1977. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Kim K. S. Comparison of cefotaxime, imipenem-cilastatin, ampicillin-gentamicin, and ampicillin-chloramphenicol in the treatment of experimental Escherichia coli bacteremia and meningitis. Antimicrob Agents Chemother. 1985 Sep;28(3):433–436. doi: 10.1128/aac.28.3.433. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Kim K. S. High-dose intravenous immune globulin impairs antibacterial activity of antibiotics. J Allergy Clin Immunol. 1989 Oct;84(4 Pt 2):579–588. doi: 10.1016/0091-6749(89)90194-2. [DOI] [PubMed] [Google Scholar]
  12. Kim K. S., Kang J. H., Concepcion N. F., Anthony B. F. Relative functional activity of purified human immunoglobulin G against a type III group B streptococcal strain. Infect Immun. 1986 Jun;52(3):908–910. doi: 10.1128/iai.52.3.908-910.1986. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Kim K. S., Kang J. H., Cross A. S., Kaufman B., Zollinger W., Sadoff J. Functional activities of monoclonal antibodies to the O side chain of Escherichia coli lipopolysaccharides in vitro and in vivo. J Infect Dis. 1988 Jan;157(1):47–53. doi: 10.1093/infdis/157.1.47. [DOI] [PubMed] [Google Scholar]
  14. McCabe W. R., Kaijser B., Olling S., Uwaydah M., Hanson L. A. Escherichia coli in bacteremia: K and O antigens and serum sensitivity of strains from adults and neonates. J Infect Dis. 1978 Jul;138(1):33–41. doi: 10.1093/infdis/138.1.33. [DOI] [PubMed] [Google Scholar]
  15. McCabe W. R., Kreger B. E., Johns M. Type-specific and cross-reactive antibodies in gram-negative bacteremia. N Engl J Med. 1972 Aug 10;287(6):261–267. doi: 10.1056/NEJM197208102870601. [DOI] [PubMed] [Google Scholar]
  16. McGowan J. E., Jr, Barnes M. W., Finland M. Bacteremia at Boston City Hospital: Occurrence and mortality during 12 selected years (1935-1972), with special reference to hospital-acquired cases. J Infect Dis. 1975 Sep;132(3):316–335. doi: 10.1093/infdis/132.3.316. [DOI] [PubMed] [Google Scholar]
  17. Orskov F., Orskov I. Escherichia coli O:H serotypes isolated from human blood. Prevalence of the K1 antigen with technical details of O and H antigenic determination. Acta Pathol Microbiol Scand Suppl. 1975 Dec;83(6):595–600. [PubMed] [Google Scholar]
  18. Orskov I., Orskov F. Escherichia coli in extra-intestinal infections. J Hyg (Lond) 1985 Dec;95(3):551–575. doi: 10.1017/s0022172400060678. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Pluschke G., Achtman M. Antibodies to O-antigen of lipopolysaccharide are protective against neonatal infection with Escherichia coli K1. Infect Immun. 1985 Aug;49(2):365–370. doi: 10.1128/iai.49.2.365-370.1985. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Setia U., Serventi I., Lorenz P. Bacteremia in a long-term care facility. Spectrum and mortality. Arch Intern Med. 1984 Aug;144(8):1633–1635. [PubMed] [Google Scholar]
  21. Söderström T., Hansson G., Larson G. The Escherichia coli K1 capsule shares antigenic determinants with the human gangliosides GM3 and GD3. N Engl J Med. 1984 Mar 15;310(11):726–727. doi: 10.1056/NEJM198403153101121. [DOI] [PubMed] [Google Scholar]
  22. Todeschini G., Vinante F., Benini F., Perini A., Pasini F., Cetto G. Gram-negative septicemia in patients with hematologic malignancies. Eur J Cancer Clin Oncol. 1984 Mar;20(3):327–331. doi: 10.1016/0277-5379(84)90077-4. [DOI] [PubMed] [Google Scholar]

Articles from Infection and Immunity are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES